Toxicarioside A inhibits SGC-7901 proliferation, migration and invasion via NF-κB/bFGF signaling

Jun-Li Guo, Shao-Jiang Zheng, Yue-Nan Li, Wei Jie, Xin-Bao Hao, Tian-Fa Li, Li-Ping Xia, Wen-Li Mei, Feng-Ying Huang, Yue-Qiong Kong, Qi-Yi He, Kun Yang, Guang-Hong Tan, Hao-Fu Dai

Jun-Li Guo, Shao-Jiang Zheng, Yue-Nan Li, Xin-Bao Hao, Tian-Fa Li, Li-Ping Xia, Feng-Ying Huang, Yue-Qiong Kong, Qi-Yi He, Kun Yang, Guang-Hong Tan, Hainan Provincial Key Laboratory of Tropical Medicine, Cancer Research Institute of Affiliated Hospital, Hainan Medical College, Haikou 571199, Hainan Province, China
Wei Jie, Department of Pathology, Guangdong Medical College, Zhanjiang 524023, Guangdong Province, China
Wen-Li Mei, Hao-Fu Dai, Key Laboratory of Tropical Crop Biotechnology, Ministry of Agriculture, Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences, Haikou 571101, Hainan Province, China

Author contributions: Guo JL, Zheng SJ and Li YN contributed equally to this work; Guo JL and Zheng SJ designed the research; Guo JL, Zheng SJ and Li YN performed the research with Jie W, Hao XB, Li TF, Xia LP, Mei WL, Huang FY; Li YN, Kong YQ, He QY and Yang K analyzed data; Zheng SJ and Guo JL wrote the manuscript; Tan GH and Dai HF revised and finally approved the article to be published.

Supported by Grants from the National Natural Scientific Foundation of China, No. 81060184; and the Natural Foundation of Hainan Province of China, No. 30864, 811201; and Program for New Century Excellent Talents in University of China, NCET-08-0657; and the National Basic Research Program of China, No. 2010CB534909; and Hainan Provincial Key Scientific Project, No. 061009

Correspondence to: Hao-Fu Dai, Professor, Key Laboratory of Tropical Crop Biotechnology, Ministry of Agriculture, Institute of Tropical Bioscience and Biotechnology, Chinese Academy of Tropical Agricultural Sciences, Haikou 571101, Hainan Province, China. hf_dai@yahoo.cn
Telephone: +86-898-66890292 Fax: +86-898-66890978
Received: September 10, 2011 Revised: January 17, 2012
Accepted: February 8, 2012
Published online: April 14, 2012

Abstract

AIM: To investigate the inhibitory role of toxicarioside A on the gastric cancer cell line human gastric cancer cell line (SGC-7901) and determine the underlying molecular mechanism.

METHODS: After SGC-7901 cells were treated with toxicarioside A at various concentrations (0.5, 1.5, 4.5, 9.0 μg/mL) for 24 h or 48 h, cell viability was determined by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay, and the motility and invasion of tumor cells were assessed by cell proliferation assay. Immunofluorescence staining, reverse transcription polymerase chain reaction and Western blotting were performed to detect the expression of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor-1 (FGFR1), and nuclear factor-kappa B (NF-κB) activation was examined by electrophoretic mobility shift assay.

RESULTS: The results showed that toxicarioside A was capable of reducing cell viability, inhibiting cell growth, and suppressing cell migration and invasion activities in a time- and dose-dependent manner in SGC-7901 cells. Further analysis revealed that not only the expression of bFGF and its high-affinity receptor FGFR1 but also the NF-κB-DNA binding activity were effectively blocked by toxicarioside A in a dose-dependent manner compared with the control group (P < 0.05 or P < 0.01). Interestingly, application of the NF-κB specific inhibitor, pyrrolidinedithiocarbamate (PDTC), to SGC-7901 cells significantly potentized the toxicarioside A-induced down-regulation of bFGF compared with the control group (P < 0.05).

CONCLUSION: These findings suggest that toxicarioside A has an anti-gastric cancer activity and this effect may be achieved partly through down-regulation of NF-κB and bFGF/FGFR1 signaling.

Key words: Anti-migration; Anti-proliferation; Basic fibroblast growth factor; Gastric cancer; Nuclear factor-kappa B; Toxicarioside A
**INTRODUCTION**

_Antiaristoxicaria_ (Pers.) _Leach_ (Moraceae) is a well known precious species widespread in the tropical rain forest of Southeast Asia. Its latex and seeds contain a complex mixture of cardenolide glycosides and is therefore toxic
de. Representative toxicariosides A-L have recently been identified from the latex and seeds of _Antiaristoxicaria_ in our laboratory and by others. Classically, cardenolides are used to treat congestive heart failure and arrhythmia. Additionally, certain cardenolides extracted from some plants or animals have been demonstrated to be capable of blocking tumor cell proliferation through regulation of cell signal transduction.

Currently, gastric cancer is one of the leading malignancies in China. However, the treatment outcome is not satisfactory because early diagnosis of gastric cancer remains difficult and most patients have already developed metastatic lesions when diagnosed.

Basic fibroblast growth factor (bFGF) has been shown to be a multifunctional growth factor for tumor development, and it exerts its biological effects mainly through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR1). Compiling evidence has demonstrated that bFGF signaling is involved in the development of gastric cancer.

Nuclear factor-kappa B (NF-κB) is a ubiquitous dimeric transcription factor that plays pivotal roles in regulating the expression of genes encoding cytokines and chemokines that are involved in tumor proliferation, angiogenesis, and synthesis of anti-apoptotic proteins. It has been documented that NF-κB can mediate bFGF signaling and it exerts its biological effects mainly through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR1). Compiling evidence has demonstrated that bFGF signaling is involved in the development of gastric cancer.

**Materials and methods**

**Plant material**

Latex of _Antiaristoxicaria_ (Pers.) _Leach_ collected in Lingshui county of Hainan Province, China in November 2005 was identified with the assistance of Professor Zhunian Wang at the Institute of Crops Genetic Resources, Chinese Academy of Tropical Agricultural Sciences. The specimen was numbered as No. AN200511.

**Chemicals and reagents**

Rabbit-anti human bFGF and FGFR1 were purchased from Santa Cruz (Santa Cruz, CA, United States). Rhodamine (TRITC)-conjugated mouse anti-rabbit immunoglobulin G (IgG), fluorescein isothiocyanate (FITC)-conjugated mouse anti-rabbit IgG, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), trypan blue and pyrrolidinedithiocarbamate (PDTC) were obtained from Sigma (Sigma Aldrich, St Louis, MO, United States). Fetal bovine serum (FBS), RPMI 1640 medium and trypsin were procured from Gibco (Gibco, Carlsbad, CA, United States).

**Extraction and isolation of toxicarioside A**

With 95% EtOH, 4.0 L of the latex of _Antiaristoxicaria_ were extracted thrice at room temperature and filtered. The combined extract was evaporated in vacuo to yield a syrup (263.8 g), which was fractionated sequentially with petroleum ether, EtOAc, and n-BuOH. The EtOAc fraction (8.68 g) that showed potent cytotoxic activity in the bioassay was passed through pressure-reduced column chromatography using step-wise elution with CHCl3-MeOH (50:1, 20:1, 10:1, 5:1, 2:1, 1:1 and 0:1, v/v), generating seven corresponding fractions, A1-A7. Fraction A7 (2.55 g) was further separated on silica gel column chromatography using step-wise elution with CHCl3-MeOH (14:1, v/v). On the basis of spectral data and chemical analyses, compound 1 was defined as toxicarioside A (Figure 1).

**Cell culture**

Human gastric cancer cell line (SGC-7901) was obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai Institute of Cell Biology. Cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 IU/mL penicillin and 100 mg/mL streptomycin at 37 °C in a humidified atmosphere with 5% CO2. Cells at the logarithmic phase were
used for experiments.

**Proliferation assay**

MTT assay and trypanblue staining were used to determine the growth and viability of SGC-7901 cells. For the MTT assay, SGC-7901 cells in logarithmic growth were trypsinized and harvested and then the cells were seeded onto a 96-well plate. After 24 h, fresh RPMI 1640 medium containing different concentrations of toxicarioside A (0.5, 1.5, 4.5, 9.0 μg/mL) was added at 100 μL per well, respectively, and 6 replicate wells were used for each of the concentrations. After incubation for different time intervals, 10 μL of MTT (5 mg/mL) was added to each well and the cells were further incubated at 37 °C for 4 h. The supernatant was then removed and 100 μL DMSO was added into each well. Absorbance (A value) at a wavelength of 490 nm was measured with a Bio-TekELX808 microplate reader (Bio-Rad, Hercules, CA, United States). For trypanblue staining, SGC-7901 cells were trypsinized and seeded into 24-well plates at a density of 0.5 × 10^4/mL. After 4.5 μg/mL toxicarioside A was added, the cells were collected and counted using trypan blue staining under an inverse light microscope for 3 consecutive days.

**Invasion and migration assay**

Invasion assays were performed in a 24-well Transwell chamber (Corning, Lowell, MA, United States) as previously described[33]. Briefly, each Transwell chamber was coated with 15 μg Matrigel, 5 × 10^4 cells were seeded to pre-coated filters in 200 μL of serum-free medium containing different concentrations of toxicarioside A (0.5, 1.5, 4.5, 9.0 μg/mL) in triplicate. The lower parts of the chambers were filled with 500 μL of RPMI 1640 medium containing 10% FBS. After incubation in a 5% CO₂ humidified incubator at 37 °C for 24 h, the cells on the upper surface were gently removed with a cotton swab, and the filters were fixed with 95% alcohol for 15-20 min and stained with hematoxylin-eosin for 15 min. The number of cells on the lower surface of the filters was quantified under a microscope. The same procedures were followed for the migration assay except the Transwell chambers were not coated with Matrigel.

**Immunofluorescence staining**

To detect the expression of bFGF as well as its receptor FGFR1 in SGC-7901 cells, the rabbit antibody (1:100) against bFGF and FGFR1 were used. The antigenic sites were localized by TRITC-conjugated mouse anti-rabbit IgG, and images of antigenic sites were captured under a laser scanning confocal microscope (FV500, Olympus, Tokyo, Japan).

**RNA extraction and reverse transcription polymerase chain reaction**

Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, United States) following the manufacturer’s protocols. Reverse transcription polymerase chain reaction was carried out using pairs of primers (Invitrogen) as follows for semiquantitative assessment: bFGF (NM_002006.4) sense, 5’-AAG AGC GAC CCT CAC ATC AA-3’; anti-sense, 5’-TCG TTT CAC TGC CAC ATC CGT CAA TA CC-3’, yielding a 225 bp product; FGFR1 (M34641) sense, 5’-CTT CGT TTG TTT AG-3’; anti-sense, 5’-TCC ACA ATG CAG GTG TAG TT-3’, yielding a 354 bp product. The products were separated by electrophoresis on a 1.5% agarose gel and visualized under UV using the gel documentation system (Bio-Rad Gel Doc1000, Bio-Rad). The mRNA levels of bFGF, FGFR1 were calculated based on the densitometric values of the specific bFGF, FGFR1 bands after adjustment with that of the β-actin band.

**Western blotting analysis**

This was performed as previously described with minor modifications[33]. Cells were homogenized and separated by sodium dodecyl sulfate-polyacrylamide gel (12.5%) electrophoresis followed by electrophoretic transfer of proteins from the gel to a nitrocellulose membrane blot (Bio-Rad). The blot was incubated with a rabbit anti-bFGF antibody (1:500) or a rabbit anti-FGFR1 antibody (1:500) at 4 °C overnight, followed by incubation with the corresponding horseradish peroxidase-conjugated antibiotin antibody (1:2000) at room temperature for 1 h. The immunoreactive signals were visualized with enhanced chemiluminescence reagents (Pierce, Rockford, IL, United States).

**Electrophoretic mobility shift assay**

To determine NF-κB activation, electrophoretic mobility shift assay (EMSA) was conducted essentially as described previously[33]. In brief, nuclear proteins (10 μg) were incubated with the reaction buffer for 20 min at room temperature, followed by incubation with oligonucleotide containing the consensus sequence for the NF-κB-DNA binding site (5’-AGAGTGGGAATT TC-3’)[33] (synthesized by Invitrogen, Shanghai, China). The reaction mixture was separated in a nondenaturing polyacrylamide gel (6%) that was later stained by SYBR Green EMSA staining solution from Molecular Probes (Invitrogen) with continuous, gentle agitation for about 20 min, protected from light. The gel was then washed in 150 mL of dH₂O and the stained nucleic acids were visualized and the image documented under UV using the gel documentation system (Bio-Rad Gel Doc1000).

**Statistical analysis**

All data are expressed as mean ± SE. For a comparison between two groups, the Student’s t test was performed. For comparisons among multiple groups, an ANOVA was carried out, followed by a Student-Newman-Keuls test. Differences were considered significant when P < 0.05.
Guo JL et al. Toxicarioside A inhibits gastric cancer

RESULTS

Effect of toxicarioside A on SGC-7901 cell proliferation
To assess the effect of toxicarioside A on the growth of gastric cancer, SGC-7901 cells were treated at various concentrations (0.5, 1.5, 4.5, 9.0 μg/mL) for 24-48 h and cell viability following these treatments was determined by MTT assays. As shown in Table 1, toxicarioside A reduced SGC-7901 cell viability in a time- and dose-dependent manner. Cell growth curves also showed that toxicarioside A significantly inhibited SGC-7901 cell growth as compared with the control (Figure 2).

Effect of toxicarioside A on SGC-7901 cell migration and invasion
The results of Transwell cell migration and invasion are presented in Table 2 and Figure 3. Clearly, the addition of toxicarioside A to the medium in the upper chamber resulted in significant suppression of SGC-7901 migration and invasion in a dose-dependent manner at 1.5, 4.5 and 9.0 μg/mL. Toxicarioside A inhibited SGC-7901 migration by 22.38% ± 10.64%, 39.58% ± 11.62% and 48.13% ± 10.12%, respectively (P < 0.05), and inhibited SGC-7901 invasion by 24.03% ± 9.06%, 44.68% ± 9.19% and 54.38% ± 8.17%, respectively (P < 0.01), as compared with the control group.

Effect of toxicarioside A on bFGF and FGFR1 in SGC-7901 cells
At the protein level, the expression of bFGF and FGFR1 was predominantly detected in the cytoplasm of SGC-7901 cells and toxicarioside A significantly decreased this expression, as assessed by immunofluorescence staining (Figure 4A) and Western blotting analysis (Figure 4C). At the mRNA level, the expression of bFGF and FGFR1 was decreased by toxicarioside A in a dose-dependent manner in SGC-7901 cells (Figure 4B).

Effect of toxicarioside A on NF-κB-DNA binding activity in SGC-7901 cells
To determine the effect of toxicarioside A on NF-κB activation, the NF-κB-DNA binding activity was determined in both toxicarioside A-treated and control SGC-7901 cells by EMSA. As shown in Figure 5, after treatment with toxicarioside A at various concentrations for 48 h, the NF-κB-DNA binding activity was decreased in a dose-dependent manner as compared with the control group (P < 0.05 or P < 0.01, Figure 5).

Effect of PDTC on toxicarioside A-induced downregulation of bFGF
To further determine whether NF-κB activation was necessary for bFGF expression, and was involved in toxicarioside A-induced downregulation of bFGF, a specific in-
Figure 4 Basic fibroblast growth factor and fibroblast growth factor receptor-1 expression in human gastric cancer cell line cells. A: The expression of basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor-1 (FGFR1) were detected using rhodamine and fluorescein isothiocyanate-conjugated mouse anti-rabbit immunoglobulin G in non-treated and toxicarioside A (4.5 μg/mL)-treated cells; B: bFGF and FGFR1 mRNA expression by reverse transcription polymerase chain reaction; C: bFGF and FGFR1 protein levels by Western blotting analysis. Results are depicted as mean ± SE of three independent experiments. *P < 0.05, **P < 0.01 vs control group.
hibitior of NF-κB activation, PDTC, was used. As shown in Figure 6, PDTC treatment significantly blocked bFGF expression, which was potentitized when both PDTC and toxicarioside A were added to SGC-7901 cells.

DISCUSSION

Antiaristoxicaria (Pers.) Lesch (Moraceae) is widespread in the tropical rain forest of southeastern Asia, and is best known for its remedial properties against injuries due to poisoned arrows, darts and blowdarts.[34]. The latex-sap and seeds of Antiaristoxicaria consists of a complex mixture of active cardenolide glycosides, from which several cardenolides have been isolated in our laboratory and other research groups[11-15]. Besides the classical effect of the cardenolides on inhibition of the ubiquitous cell surface Na⁺, K⁺-ATPase, the effect of cardiac glycosides on the growth of human malignant tumor cells has been reported in the recent past[16-19]. In the present work, we investigated the anti-cancer activity of toxicarioside A isolated from the latex of Antiaristoxicaria. Both the MTT assay and the growth curve analysis revealed that toxicarioside A resulted in inhibition of gastric cancer cell proliferation in a dose- and time-dependent manner. Malignant tumors are characterized by invasion and metastasis, an extremely complex process involving multi-steps. In this study, we assessed the migrating and invasive capabilities of SGC-7901 cells using the Transwell chamber assay. The results demonstrated that toxicarioside A not only suppressed cell motility, but also significantly reduced its ability to degrade the recombinant basement membrane in SGC-7901 cells.

To further investigate the molecular mechanism underlying the anti-tumor properties of cardenolides, we assessed the effect of toxicarioside A on bFGF expression in SGC-7901 cells. It is well known that bFGF, a regulatory factor secreted from cells, is involved in a variety of biological processes including cell differentiation, cell growth, migration, angiogenesis, and tumor formation[19,20]. The biological effect of bFGF is achieved mainly through interaction with its high-affinity receptor, FGFR1[21-23]. To elucidate whether the bFGF/FGFR1 signaling pathway was a target of toxicarioside A in gastric cancer cells, we evaluated changes in the expression of bFGF and FGFR1 in SGC-7901 cells after treatment with toxicarioside A at various concentrations. The results demonstrated that toxicarioside A down-regulated the expression of bFGF and FGFR1 at both mRNA and protein levels in SGC-7901 cells in a dose-dependent manner.

Next, we sought to investigate the molecules involved in the toxicarioside A-induced down-regulation of bFGF in SGC-7901 cells. The NF-κB signaling pathway is a central common regulator for the process of inflammation, viral replication, tumorigenesis, and apoptosis[27,38], and as a result has emerged as a potential target of numerous pharmaceutical agents[39,40]. Our results showed that toxicarioside A had an obvious suppressive effect on NF-κB-DNA binding activity in a dose-dependent manner, and treatment with an NF-κB specific inhibitor augmented the toxicarioside A-induced bFGF down-regulation in SGC-7901 cells, suggesting that the activated NF-κB may be partly necessary for bFGF expression in gastric cancer.

In summary, toxicarioside A weakened the abnormal activation of NF-κB to down-regulate the expression of bFGF, which in turn, interfered with bFGF/FGFR1 signal transduction subsequently leading to suppression of proliferation, migration and invasion in SGC-7901 cells. Future research will focus on identification of new targets to provide the theoretical basis for the potential
application of toxicarioside A in the clinical treatment of gastric cancer.

COMMENTS

Background

The latex and seeds of Antiaristoxicaria contain a complex mixture of cardenolide glycosides, and representative toxicariosides A-L have recently been identified in our laboratory and by others. Some cardenolides have been demonstrated to be capable of blocking tumor cell proliferation through regulation of cell signal transduction.

Research frontiers

Gastric cancer is one of the leading malignancies in China. However, the treatment outcome is not satisfactory because early diagnosis of gastric cancer remains difficult and most patients have already developed metastatic lesions when diagnosed. It is important to investigate the strategies that could inhibit gastric cancer effectively.

Innovations and breakthroughs

To date, little is known about the underlying mechanism regarding the anti-cancer effects of toxicarioside A. Therefore, this study was conducted to investigate the anti-cancer activity of toxicarioside A on gastric cancer growth and migration and the underlying molecular mechanisms in vitro.

Applications

This study indicates the first evidence of the underlying molecular mechanisms of the anti-cancer activity of toxicarioside A in gastric cancer. These results provide the theoretical basis for the potential application of toxicarioside A in the clinical treatment of gastric cancer.

Terminology

Antiaristoxicaria (Pers.) Leach (Moraceae) is a well known precious species widespread in the tropical rain forest of Southeast Asia, and the latex and seeds of Antiaristoxicaria consist of a complex mixture of active cardenolid glycosides.

Peer review

This manuscript showed toxicarioside A inhibits the proliferation, invasion and migration in a gastric cancer cell line, and these phenomena were correlated with down-regulation of nuclear factor-kappa B/basic fibroblast growth factor signaling. The design of study is solid and experiments were elegantly performed.

REFERENCES

1 Shrestha T, Kopp B, Bisset NG. The Moraceae-based dart poisons of South America. Cardiac glycosides of Maquira and Nauclease species. J Ethnopharmacol 1992; 37: 129-143
2 Dong WH, Mei WL, Zhao YX, Zeng YB, Zuo WJ, Wang H, Li XN, Dai HF. Cytotoxic cardenolide glycosides from the seeds of Antiaris toxicaria. Plant Med 2011; 77: 1730-1734
3 Dong WH, Mei WL, Zhao YX, Zeng YB, Wang H, Dai HF. A new drimane sesquiterpenoid glycoside from the seeds of Antiaris toxicaria. J Asian Nat Prod Res 2011; 13: 561-565
4 Dai HF, Gan YJ, Que DM, Wu J, Wen ZC, Mei WL. Two new cytotoxic cardenolides from the latex of Antiaris toxicaria. J Nat Prod Res 2009; 11: 832-837
5 Dai HF, Gan YJ, Que DM, Wu J, Wen ZC, Mei WL. A new cytotoxic 19-nor-cardenolide from the latex of Antiaris toxicaria. Molecules 2009; 14: 3694-3699
6 Shi LS, Liao YR, Su MJ, Lee AS, Kuo PC, Damu AG, Kuo SC, Sun HD, Lee KH, Wu TS. Cardiac glycosides from Antiaris toxicaria with potent cardiacotonic activity. J Nat Prod 2010; 73: 1214-1222
7 Ghoseghiade M, van Veldhuisen DJ, Colucci WS. Contemporay use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113: 2556-2564
8 Hamad E, Mather PJ, Srinivasan S, Rubin S, Whellan DJ, Feldman AM. Pharmacologic therapy of chronic heart failure. Am J Cardiovasc Drugs 2007; 7: 235-248
9 Choedon T, Mathan G, Arya S, Kumar VL, Kumar V. Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 2517-2522
10 Yeh YJ, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003; 54: 112-124
11 Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmidt RA. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006; 66: 5867-5874
12 Sreenivasan Y, Sarkar A, Manna SK. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol 2003; 66: 2223-2239
13 McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000; 60: 3807-3812
14 Lin J, Denmeade S, Carducci MA. HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. Curr Cancer Drug Targets 2009; 9: 881-887
15 Newman RA, Yang P, Pawlus AD, Block KL. Cardiac glycosides as novel cancer therapeutic agents. Mol Inter Med 2008; 8: 36-49
16 Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 2007; 46: 277-285
17 Ribatti D, Vacca A, Rusnati M, Presta M. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev 2007; 18: 327-334
18 Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG. Basic FGF augments hypoxia induced HIF-1alpha expression and VEGF release in T47D breast cancer cells. Pathology 2007; 39: 396-400
19 Smith JA, Madden T, Vijeswarapu M, Newman RA. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC-3 and DU145 by Avnirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 2001; 62: 469-472
20 Cronauer MV, Hittmair A, Eader IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H. Basic fibroblast growth factor level factors in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997; 31: 223-233
21 Giehl KA, Nagle U, Volkenandt M, Berking C. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma. J Cutan Pathol 2007; 34: 7-14
22 Fortin D, Rom E, Sun H, Yayon A, Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005; 25: 7470-7479
23 Udayakumar TS, Klein RD, Maliner MS, Nagle RB, Bowden GT. Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promotrypsin expression by fibroblast growth factors. Int J Cancer 2001; 91: 187-192
24 Kamura S, Matsumoto Y, Fukushima JI, Fujiwara T, Iida K, Okada Y, Iwamoto Y. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing’s sarcoma family of tumours by activating the FGRF1-Pi3K-Rac1 pathway. Br J Cancer 2010; 103: 370-381
25 Gong J, Morishita A, Kurokohchi K, Tani J, Kato K, Miyoshi H, Inoue H, Kobayashi M, Liu S, Murota M, Muramatsu A, Izuishi K, Suzuki Y, Yoshida H, Uchida N, Deguchi K, Iwama H, Ishimaru I, Masaki T. Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. J Gastrointest Surg 2006; 10: 101-106
26 Katoh M, Katoh M. FGF signaling network in the gastroin...
testinal tract (review). *Int J Oncol* 2006; 29: 163-168

27 **Baldwin AS**. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. *J Clin Invest* 2001; 107: 241-246

28 **Nakanishi C**, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. *Nat Rev Cancer* 2005; 5: 297-309

29 **Bushdid PB**, Chen CL, Brantley DM, Yull F, Raghow R, Kerr LD, Barnett JV. NF-kappaB mediates FGF signal regulation of mxe-1 expression. *Dev Biol* 2001; 237: 107-115

30 **Yang Q**, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy H, Srivastava M, Esposito D, Gillette W, Hartley J, Pollard HB. Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. *Proc Natl Acad Sci USA* 2005; 102: 9631-9636

31 **Mijatovic T**, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. *Med Cancer Ther* 2006; 5: 391-399

32 **Peng L**, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, Sun YM, Sun LC, Pan J, Sun LX, Zhao P, Yang ZH. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. *Carcinogenesis* 2009; 30: 1660-1669

33 **Zheng SJ**, Zheng SP, Huang FY, Jiao CL, Wu RL. Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.

---

**Guo JL et al.** Toxicarioside A inhibits gastric cancer

*World J Gastroenterol* 2007; 13: 2484-2489

34 **Guo J**, Jie W, Kuang D, Ni J, Chen D, Ao Q, Wang G. Ischaemia/reperfusion induced cardiac stem cell homing to the injured myocardium by stimulating stem cell factor expression via NF-kappaB pathway. *Int J Exp Pathol* 2009; 90: 355-364

35 **Ueda A**, Ishigatsubo Y, Okubo T, Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. *J Biol Chem* 1997; 272: 31092-31099

36 **Jiang MM**, Dai Y, Gao H, Zhang X, Wang GH, He JY, Hu QY, Zeng JZ, Zhang XK, Yao XS. Cardenolides from Antiaris toxicaria as potent selective Nur77 modulators. *Chem Pharm Bull (Tokyo)* 2008; 56: 1005-1008

37 **Baldwin AS**. Series introduction: the transcription factor NF-kappaB and human disease. *J Clin Invest* 2001; 107: 3-6

38 **Giri DK**, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. *J Biol Chem* 1998; 273: 14008-14014

39 **Namba H**, Saenko V, Yamashita S. Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. *Arq Bras Endocrinol Metabol* 2007; 51: 843-851

40 **Lee JI**, Burckart GJ. Nuclear factor kappa B: important transcription factor and therapeutic target. *J Clin Pharmacol* 1998; 38: 981-993

S- Editor Gou SX  L- Editor Webster JR  E- Editor Li JY